2023
DOI: 10.1177/00438200231177462
|View full text |Cite
|
Sign up to set email alerts
|

The Red Flag of Emergency Use Authorization (Eua)

Abstract: The Emergency Use Authorization (EUA) policy, a representative biodefense policy, was legislated in the United States in 2001 based on lessons learned from Amerithrax, whereas Korea's EUA policy was based on lessons learned from the Middle East Respiratory Syndrome outbreak in 2015. Due to these divergent origins, the U.S. EUA's homeland security objectives were specialized to deal with highly pathogenic biological agents that could be exploited for bioterrorism, whereas the Korean EUA pursues disease containm… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 43 publications
0
2
0
Order By: Relevance
“…Due to the rapid spread of COVID-19, the FDA has begun issuing Emergency Use Authorization (EUA) for multiple COVID-19 diagnostic tests (Table 3). 369 Notably, experiments with the FDA-EUA status are not granted full FDA approval, 370 instead their authorizations are only valid for the duration of the pandemic. EUA assays for COVID-19 are administered by the clinical laboratory.…”
Section: Commercially Available Diagnostic Devices To Combat Sars-cov-2mentioning
confidence: 99%
“…Due to the rapid spread of COVID-19, the FDA has begun issuing Emergency Use Authorization (EUA) for multiple COVID-19 diagnostic tests (Table 3). 369 Notably, experiments with the FDA-EUA status are not granted full FDA approval, 370 instead their authorizations are only valid for the duration of the pandemic. EUA assays for COVID-19 are administered by the clinical laboratory.…”
Section: Commercially Available Diagnostic Devices To Combat Sars-cov-2mentioning
confidence: 99%
“…Next, we have two articles dealing in depth with aspects of the pandemic concerning the transnational effect(s) of COVID-19 on stock indexes (Tavor and Teitler-Regev 2023) and an illuminating study comparing institutional conflict resulting in different COVID-19 testing outcomes in the United States and South Korea (Kim 2023). This last paper is highly recommended reading for its breadth of information as much as the solidity (and rather sobering conclusions) of its comparative analysis.…”
Section: Fall 2023 Issue Previewmentioning
confidence: 99%